A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION - Regional Cancer Care Associates LLC

Clinical Trials

A PHASE 1 MULTI-CENTER, OPEN-LABEL, DOSE ESCALATION STUDY TO DETERMINE THE PHARMACOKINETICS AND SAFETY OF POMALIDOMIDE WHEN GIVEN IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

Type of Cancer
Multiple Myeloma
Locations
Hackensack
Sponsor
Celgene
Protocol Number
CC-4047-MM-008
Cancer Diagnosis
To Learn More Call
201-510-0910